Christopher Thomas

Christopher Thomas

Auto-generated profile, based on publicly available information

Christopher Thomas

Department of Medical Oncology and Hematology Wake Forest Baptist Medical Center Winston-Salem NC USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2020 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DMDean McKenzie
Dean McKenzie
CTChristopher Thomas
Christopher Thomas

20 February 2018 in European Journal of Cancer Care
Verified
Journal Article
Closed access
PDF file
CTC. Thomas
C. Thomas
AWA. C. Wootten
A. C. Wootten
PRP. Robinson
P. Robinson
PLP. C. F. Law
P. C. F. Law
DMD. P. McKenzie
D. P. McKenzie

1 November 2020 in Case Reports in Urology
Verified
Journal Article
Open access
PDF file
TPTaylor C. Peak
Taylor C. Peak
EFElena Fenu
Elena Fenu
MRMichael Rothberg
Michael Rothberg
CTChristopher Thomas
Christopher Thomas
RDRonald Davis
Ronald Davis
ELEdward A. Levine
Edward A. Levine
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a patient with a 13.9cm left renal mass and significant retroperitoneal and iliac lymphadenopathy, classified as intermediate-risk mRCC. We discuss and review the literature on complete responses after systemic therapy and the ability to predict who has undergone a complete response in the face of residual radiographic evidence of disease.